MedTrace Logo

Severe Asthma, MepolizumaB and Affect: SAMBA Study

NCT04680611 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-10-06

No results posted yet for this study

Summary

This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).

Conditions

  • Severe Eosinophilic Asthma
  • Psychological Distress
  • Anxiety
  • Depression
  • Psychological Stress
  • Psychological Adjustment
  • Psychological Disorder
  • Psychosocial Problem
  • Psychosocial Stressor
  • Psychological
  • Emotions
  • Emotional Disorder
  • Emotional Dysfunction
  • Emotional Distress
  • Adjustment
  • Adjustment, Emotional
  • Coping Behavior

Interventions

OTHER

no study intervention. Patients receive standard clinical care

no intervention. observational study

Sponsors & Collaborators

  • Portsmouth Hospitals NHS Trust

    collaborator OTHER_GOV

  • University of Derby

    collaborator OTHER

  • University Hospital Southampton NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04680611 on ClinicalTrials.gov